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SUMMARY
A chlamydial glycolipid antigen (GLXA) is shed into the medium of C. trachomatis-infected cell
cultures. This study screened monoclonal antibodies (mAb), prepared in different laboratories by
immunization with embryonated egg propagated elementary bodies (EB), for their ability to bind
with infected cells and to react with purified GLXA isolated from supernatants of infected McCoy
cells. The fluorescent antibody (FA) staining pattern exhibited by a number of mAb indicated that
they bound antigen present within the inclusion and at the inner membrane surface of infected cells;
the observed pattern differs significantly from the distribution seen when anti-lipopolysaccharide
(LPS) (mAb) were used. The staining pattern observed by immunofluorescence was confirmed and
extended by ultrastructure studies of immunogold-labelled, infected human endometrial gland
epithelial cells (HEGEC) and a human endometrial carcinoma-derived cell line (RL95-2).
Additionally, the immunoclectron microscope studies revealed binding within the inclusion and on
reticulate bodies, within the cell cytoplasm and at the surface of infected cells. The specificity of the
reactive mAb, examined by molecular shift chromatography and isolated, affinity-purified GLXA,
indicated that two mAb of the IgG isotype recognized an antigen which had been purified from tissue
culture supernatants by affinity chromatography using an IgM mAb. The results suggest that GLXA
is an important determinant whose role and function during in vitro and in vito infections deserves
further analyses.
INTRODUCTION
Previous studies have indicated that ChlamiXdia trachoinatis
produce and release a glycolipid antigen during the course of
cultivation in vitro' and that human sera from patients with
Abbreviations: Ap, IgM monoclonal affinity purified; BSB, borate-
buffered saline; COM, complete overlay media; EBs, chlamydial
elementary bodies; EB-cs, elementary bodies from embryonated eggs;
EIA, enzyme-linked immunoassay; ETOH, ethanol; FA, fluorescent
antibody; Fc, immunoglobulin constant fragment; FCS, foetal calf
serum; GLXA, chlamydial glycolipid exoantigen; HEGEC, human
endometrial gland epithelial cell; H&L, heavy and light chains of Ig;
HRP, horseradish peroxidase; IgM, immunoglobulin M isotype; Ip,
initial Octyl-Sepharose purification of GLXA; LGV, lymphogranu-
loma venerium; mAb, monoclonal antibody; ml/eq, antigen containing
concentrate equivalent to millilitres of culture supernatant; MEOH,
methanol; PBS, phosphate-buffered saline; RB, reticulate body; ReLPS,
Re mutant 595 of S. minnesota; RL95-2, human endometrial carcinoma
cell line; TEM, transmission electron microscopy; TCA, trichloroacetic
acid; TMB, 3,3',5,5'-tetramethylbenzidine.
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clinically defined lymphogranuloma venerium (LGV) contain
IgG antibodies which recognize glycolipid that has been
affinity-purified from tissue culture supernatants.2 This finding
suggested the glycolipid is produced during a natural infection
in tito. Obtaining specific monoclonal antibodies (mAb) and
utilizing them to detect glycolipid distribution in infected cells
would provide a key to assessing the possible role of this
apparently dominant epitope during the natural infectious
process.
A series of studies, therefore, was undertaken to examine,
first, the distribution of glycolipid in infected cells, and then
assess the reactivity ofmAb presenting a strong staining pattern
in fluorescent and ultrastructural analyses; the ultrastructural
studies would provide more definitive evidence of the localiza-
tion of chlamydial glycolipid exoantigen (GLXA) within
infected cells. mAb presenting a common binding pattern were
examined for their reactivity with the isolated glycolipid. Since
glycolipid did not consistently bind to microtitre wells, the
reactivity ofmAb with GLXA could not be assessed by enzyme-
linked immunoassay (EIA). Instead, mAb-GLXA binding, as
well as competition between different antibodies for binding
with GLXA, was examined by molecular shift chromato-
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graphy.3 Importantly, while assessment by this method is more
cumbersome, it has the advantage of being carried out in liquid
phase and so the natural configuration of GLXA is retained
during interaction with antibodies.
The findings from these studies support four general conclu-
sions. First, a number ofmAb, generated by immunization with
chlamydial elementary body (EB), harvested from embryonated
eggs (EB-cs), react with glycolipid isolated from culture medium
of infected cells. Second, the glycolipid is localized not only
within the chlamydial inclusion body but is also found in the
inclusion membrane, the host cell cytoplasm, host cell surface
and the surrounding micro-environment. Third, the molecular
shift data indicate that at least some of the mAb which recognize
the glycolipid antigen compete for binding to the same, or
overlapping, epitopes. Finally, the evident competition demon-
strated between different mAb strongly suggests that GLXA is a
normal component of both EB and reticulate body (RB) forms
and quite antigenic, routinely eliciting antibody production.
MATERIALS AND METHODS
Cultivation of C. trachomatis
Cultivation essentially followed the methods described pre-
viously,4 except as follows. McCoy cells were used and cell
division was inhibited with cycloheximide (1 jug/ml; Whittacker
overlay medium; Whittacker, Walkersville, MD). Serovars A,
B, C and F also were grown in Corning roller bottles (Fisher
Scientific, Pittsburg, PA) seeded with McCoy cells in 150 ml
IMEMZO (Irvine Scientific, Santa Ana, CA) containing 30%
foetal calf serum (FCS). At confluence, medium was replaced
with 0 5-3 ml of inoculum in complete overlay medium. After
rolling (3 r.p.m.) for 2 hr at 35°, 200 ml of complete overlay
medium were added to the bottles. Incubation continued at 35',
3 r.p.m., until termination. C. trachomatis, E/UW-5/Cx, a
human urinogenital isolate, and lymphogranuloma venerium
(LGV) (L2/434/BU) were cultivated in McCoy cells as described
by Moorman et al.5 Human endometrial gland epithelial cells
(HEGEC) and the human carcinoma cell line (RL95-2) were
cultivated following previously described protocols.5'6
Monoclonal production
mAb were prepared by inoculating purified LGV-2 organisms
from embryonated eggs (EB-cs) into BALB/c ByJ mice. Hybri-
doma cells were prepared by polyethylene glycol fusion of
mouse myeloma cells (SP2/0 Ag 4-1) with spleen cells from the
immunized mice following the method of Galfrie & Milstein.7
Antibody secretion was assessed by EIA screening for binding
by hydridoma supernatants to microtitre wells coated with
chlamydial EB. Bound immunoglobulin was detected with
horseradish peroxidase (HRP) conjugated protein-A. Super-
natants were tested against all 15 serovars of C. trachomatis,
C. psittaci 6BC and meningopneumonitis to demonstrate recog-
nition of a genus antigen. mAb were isotyped with the Zymed
MonoAB ID EIA kit (Zymed Lab Inc., San Francisco, CA).
Alternatively, Renografin-purified, culture grown L2 serovar
organisms were injected into BALB/c ByJ mice. An initial
GLXA preparation (Ip), isolated from serovar B-infected
McCoy cells as described previously,4 provided in vitro stimula-
tion of spleen cells removed from primed animals. The resultant
hybridomas were screened for binding to GLXA and EIA-
positive clones were grown as ascites. An IgM mAb was isolated
either by gel-filtration through Sepharose CL 6B (Pharmacia/
LKB; Piscataway, NJ) or by low salt precipitation and used to
prepare an affinity column.
Affinity purification
Initial preparations were isolated from supernatants of control
or infected McCoy cell cultures as previously described.4
Samples, in phosphate-buffered saline (PBS), were affinity
purified by filtration over an Affigel-10 (Bio-Rad, Richmond,
CA) column (07 x 5-0 cm) to which anti-GLXA IgM was
coupled according to the manufacturer's specifications. Bound
material was eluted in high salt, desalted by passage over Octyl-
Sepharose CL 4B and stored at - 20° until used. Samples were
assessed using the PhastSystemTM (Pharmacia) SDS-PAGE as
described previously.2'4
External labelling ofantibody preparations
IgG was labelled with '25lodine as described previously.2 Briefly,
10-25 ,ul of antibody containing mouse ascites were labelled
using enzymobeads from Bio-Rad (Richmond, CA) and, subse-
quently, the 155,000 MW fraction was isolated by gel-filtration
chromatography.
Molecular shift chromatography
Glycolipid does not consistently bind well to microtitre plates so
GLXA/antibody interaction was assessed using molecular shift
chromatography as described previously.2'3 Antigen prepara-
tions were combined either with isolated IgG or the IgG-
containing fractions of '25l-labelled ascites fluid, then gel
filtered. The larger molecular weight of GLXA/IgG complexes
causes them to elute earlier from a gel filtration column than
does IgG alone and they can be detected by absorbance at
280 nm and/or the c.p.m. of the 1-ml fractions. 1251 isotope
emissions were detected with a Beckman 4000 Gamma counter.
In competition experiments, EIA verified the presence of
unlabelled, competing IgG in the eluant. Briefly, I 00-ll aliquots
were incubated in Dynatech Immunolon I Removawell strips
(Dynatech, Chantilly, VA); after blocking, I hr with 1% BSA/
PBS, bound antibody was detected using HRP-conjugated goat
anti-rabbit or rabbit anti-mouse IgG (H&L specific, Jackson
Immunochemical Laboratory, West Grove, PA), diluted 1: 1000
in PBS. Absorbance at 650 nm of the TMB substrate (Kirke-
gaard and Perry, Gaithersburg, MD) was quantified with a Vmax
Kinetic Plate Analyzer (Molecular Devices, Palo Alto, CA).
Fluorescent antibody staining
Indirect fluorescent antibody (FA) staining of fixed cells
followed the method of Nichols & McComb.8 Infected cells,
grown on 12-mm coverslips in 24 multiwell plates (Fisher
Scientific, Pittsburg, PA) were fixed with ice-cold MEOH and
stored at -20' until used. Subsequently, samples were incu-
bated with anti-chlamydial or control antibody for 30 min at
37G. Bound primary antibody was detected by incubation for 30
min at 37° with an Fc-specific, rhodamine-conjugated rabbit
anti-mouse IgG (Jackson Immunochemical Laboratories, West
Grove, PA). Photography utilized an Olympus 25, 35 mm
camera (ASA 1600 Kodak film) mounted on a Zeiss A.7082
Oberkichen microscope, illuminated with a 12v/100z halogen
lamp.
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Ininiunogoldl labelling
A hormone responsive, human endometrial carcinoma-derived
cell line RL-95-29 or primary HEGEC were cultivated and
infected with C. traclhonmtis as described previously. Cells,
fixed with 2', paraformaldehyde-05%, gluteraldehyde in 0 1 M
Sorsenson buffer (pH 7 2), were embedded in Lowicryl K4M,
using the procedure of Carlemalm ct al.") for low temperature
preparation for immunoelectron microscopy. Thin sections, cut
with glass knives, were collected on nickel grids and immunola-
belled by a procedure adapted from Timms."
RESULTS
The cellular distribution ofGLXA during in vitro infection was
explored. Infected McCoy cells were examined at selected times
post-infection by FA staining and the fluorescent pattern of
mAb 89MS30, shown in Fig. 1, is typical of various mAb tested.
The staining was characterized as follows: (i) inclusion bodies
exhibited very bright fluorescence; (ii) fluorescence was appar-
ent in the vacuole space surrounding this mass; (iii) in addition,
fluorescence was localized apparently around the inner surface
of the inclusion membrane as well as the infected cell surface
(Fig. Ia, b, c). No fluorescence was demonstrated in controls,
which consisted of identically infected cells, probed with normal
mouse IgG and a Rhodamine-conjugated, affinity-purified
second antibody (Fig. Id).
To verify that the GLXA distribution observed for McCoy
cells was not unique to this cell line, and to more specifically
localize the C. traclhoniatis antigen binding, immunoelectron
microscope studies of serovar E-infected RL95-2 cells were
carried out. Figure 2 is representative of the immunogold
labelling pattern on thin sections exposed to monoclonal
89MS30. Gold particles were evident within the inclusion,
associated with developing RB and within the 'space' of the
inclusion. Additionally, the inclusion membrane, the rim of
cytoplasm surrounding the inclusion, the cell-surface and the
extracellular space were labelled (Fig. 2a, b). Uninfected cells
processed identically showed limited background binding and
no significant accumulations of gold particles (Fig. 2c).
In a third study, primary differentiated human endometrial
epithelial cells were infected with the more virulent and invasive
LGV serotype. In Fig. 3, TEM micrographs demonstrate that
significant quantities of 89MS30 mAb binding material were
present and have the same general distribution as was observed
for serovar E-infected RL95-2 cells (cf. Fig. 2a, b). LGV-
infected cells, however, appeared to contain more mAb binding
material, both within the inclusion space and associated with the
developing organisms. As a control, HEGEC cells infected with
LGV were stained with the gold-conjugated second affinity
antibody only, omitting the primary mAb, to show there was no
significant non-specific binding (Fig. 3c). Thus, both ultrastruc-
ture series confirmed GLXA in the inclusion, and on RB.
Additionally they demonstrated GLXA in inclusion-associated
cytoplasm, and in the surrounding extracellular space.
To demonstrate the mAb binding constituted specific recog-
nition ofGLXA, a number ofmAb which had presented similar
binding patterns were tested. Since microtitre plates are variable
in their binding capacity for GLXA, recognition ofGLXA was
assessed using the more cumbersome method of molecular shift
chromatography rather than EIA. The molecular weight of the
complex formed by antigen and its cognate antibody was greater
Figure 1. Monoclonal antibody staining. Fixed McCoy cells, infected
with serovar B EB and probed with anti-GLXA mAb (89MS30) or
normal mouse IgG to detect GLXA distribution by fluorescent staining.
(a) McCoy cells 36 hr post-infection; (b) McCoy cells 48 hr post-
infection with fluorescent material at the surface and a distribution like
that noted in (a): (c) control, McCoy cells 72 hr post-infection, treated
with normal mouse IgG. Note absence of fluorescent staining in (d).
Magnification x 1000.
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Figure 2. TEM immunogold staining of RL95-2 cells. Thin sections of
RL95-2 cells infected with serovar E (a, b) or uninfected (c) probed with
anti-GLXA mAb (89MS30; 1/100 in I O, ovalbumin/PBS) followed by
colloidal gold-conjugated goat anti-mouse (1/50 in I 0% ovalbumin/PBS)
to detect the distribution of GLXA. Magnification: (a) x 27,000;
(b) x 36,000; (c) x 42,000. Note minimal binding to cross-reactive
epitopes on the eukaryotic cell (c).
than the weight of either component alone, therefore during gel
filtration complexes eluted earlier than IgG alone. Initially, the
dose dependency of the molecular shift peak size was verified by
examining the absorbance profiles from interaction of different
quantities of GLXA with a standard concentration of purified
rabbit polyclonal anti-chlamydia IgG antibody. The observed
absorbance at 280 nm (Fig. 4) demonstrated that larger
quantities of antigen generated increasingly larger peaks eluting
just after the column void volume. Thus, peak size was a
quantitative reflection of antibody binding with antigen. Nor-
mal IgG did not produce a shift peak (data not shown).
Figure 3. TEM immunogold staining of HEGEC cells. Thin sections of
HEGEC cells infected with LGV (a, b) HEGEC cells treated with
89MS30, followed by colloidal gold conjugate as described in Fig. 2.
(c) Control, infected cells incubated only with the colloidal gold second
antibody; note absence of non-specific labelling by the colloidal gold
treatment. Magnification: (a) x 21,400. (b) x 28,000; (c) x 33,250.
The molecular shift technique was utilized next to verify that
complex formation was antigen specific. Material, purified from
control and infected culture supernatants utilizing an IgM
affinity column, was reacted separately with aliquots of mAb
89MS30 IgG, gel filtered and the fraction aliquots tested by EIA
to detect mouse IgG. Figure 5 shows a typical profile of
absorbance at 650 nm. Two facts are evident: (i) mAb interacted
with the affinity-purified GLXA, but not with control material,
to form a multifraction shift peak; and (ii), as expected, mouse
IgG molecules were present in this peak. Thus, the mAb
recognized and specifically bound with the GLXA.
Subsequently, different mAb were screened using affinity
purified, native GLXA, to assess and partially quantify their
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Figure 4. Dose-dependency of complex peak. Profiles
280 nm generated by different quantities of Octyl-Se
(Ip) glycolipid antigen reacting with IgG from rabbits
purified C. trachomatis EB-cs. The doses of antigenuz
ml/eq, are equivalent, respectively, to volumes of 25
75 (0) ml of supernatant from heavily infected culturn
recognition of GLXA and to estimate possible
(Fig. 6). Radiolabelled 89MS30 was reacted
GLXA and gel filtered. Subsequently, aliquot
preparations of GLXA and radiolabelled mAb i
with a second, unlabelled mAb (89MS35). This
graphed in Fig. 6 and demonstrates significant
c.p.m. in the shift peak, suggesting the unlabel
peted with the labelled antibody for antigen binc
of Fig. 6 shows the absorbance at 650 nm gener
post-void volume fractions which detected signifi
of mouse IgG. The presence of IgG, despiteth
diminution of c.p.m. from the radiolabelledQ
supports the conclusion that the unlabelledm}
competed with a different, radiolabelled mA
binding. A second set of mAb, of which one wa
and the other was not, was similarly tested
essentially the same results in terms of reactivil
and ability to compete for binding to GLX/
radiolabel experiments indicate that different m
compete with each other for binding with GLX/
may recognize overlapping, or closely associate
Finally, experiments were carried out with;
IgG preparation from immune rabbit serui
demonstrated by EIA to have a high titre against
grown in embryonated eggs. Initial moleculk
suggested the presence of a GLXA-specific subpopulation of
0o antibody molecules. Additional assays with this radiolabelled
rabbit IgG, GLXA and a GLXA-specific monoclonal verified
this subpopulation. As Fig. 7 illustrates, the level of radiola-
belled rabbit antibody in the post-void volume shift peak
fractions was significantly diminished in the presence of mono-
clonal 89MS30. Thus, among the rabbit B-cell clones, a
significant portion produces antibody which interacts with the
epitope recognized by the mouse monoclonal, and the mouse
antibody can displace the rabbit antibody binding in the
antigen/antibody complexes.
In each set of experiments, the same number of total c.p.m.
and quantity of GLXA were used. Data from the different
molecular shift assays therefore could be examined to deter-
mine, quantitatively, the decrease in c.p.m. associated with
antibody competition. These comparisons are presented in
Table 1 and illustrate three main points: (i) different mAb of the
IgG isotype are reactive with the glycolipid purified with anIgM
ligand affinity column; (ii) simultaneous interaction of two
different mAb with affinity-purified GLXA demonstrated a
quantitatively significant competition for binding with the
antigen, resulting, for example, in a 69%/. decrease in the number
of c.p.m. in the antigen/antibody complex-containing fractions;
(iii) the rabbit polyclonal antibody also reacted with the GLXA
80 100 purified by affinity chromatography, and in the presence of an
anti-GLXA monoclonal the binding of radiolabelled rabbit
antibody was diminished by 75%', suggesting it recognized the
of absorbance at GLXA epitope; (iv) polyclonal interaction with non-affinity
pharose-isolated purified GLXA versus affinity-purified GLXA demonstrated an
immunized with increase of 54%/0 in the c.p.m. of the shift peak fractions. A
sed, expressed as broader spectrum of radiolabelled rabbit antibodies should
s(), 50 (K>) or recognize the broader spectrum of epitopes present in the non-
affinity purified sample and therefore generate a larger peak
containing antigen/antibody complexes.
cross-reactivity DISCUSSION
with purified GLXA is a genus-specific chlamydial antigen distinctly different
ts of the same from genus-specific LPS. The major differences include: (i)
were combined abundant secretion into the medium of infected cell cultures;
profile is also (ii) facile isolation; (iii) a distinct banding pattern on SDS-
diminution of PAGE, and (iv) a different isoelectric point.2 That the structures
lied Mab com- of GLXA and LPS'6 are disparate has been confirmed by
ling. The insert chemical analyses.4 No KDO, heptose, glucosamine, nor the
ated byEIA of fatty acids normally associated with lipid A, have been identified
icant quantities in GLXA preparations. Instead, gulose, mannose and possibly
e concomitant galactose constitute the major antigenic determinant and only
89MS30 mAb, two fatty acids appear to be associated with the purified
kb successfully antigen.'7 It is notable that antibodies to GLXA are present in
Lb for GLXA the antisera of individuals undergoing chlamydial infection and
s radiolabelled therefore GLXA may play a significant role in the process of
and produced infection, the replication of the organism, and the immune
ty with GLXA response of the host including, perhaps, the immunopathology
\. Thus, these associated with disease.2
louse mAb can To begin delineating the function(s) in cellular biology for
k and therefore GLXA, observations of light and TEM samples were carried
d, epitopes. out and the results permit a number of conclusions. (i) The
radiolabelled antigen is displayed at the surface of infected cells and within the
m (88MS334), inclusion body itself. (ii) Inside the inclusion, antigen is
chlamydial EB distributed on developing chlamydia, within the inclusion space,
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Figure 5. Specificity of complex peak. Profile of absorbance at 650 nm of aliquots of column fractions tested by EIA. Affinity-purified
samples ofcontrol or of glycolipid material were reacted with monoclonal 89MS30 (IgG) subjected to molecular shift chromatography.
The graph shows the profile at 650nm of selected fractions ofcolumn eluant. The insert plots the absorbance ofcomplex peak fractions.
Note the significant difference in the detectable mouse IgG eluting in post-void volume fractions when affinity purified GLXA (-) rather
than control (0) sample was used for antigen/antibody complex formation.
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Figure 6. Cold competition. EIA profile of column fractions from
competition between different monoclonals (89MS30, IgG and
89MS35-IgG) for binding to affinity-purified GLXA. The insert in-
dicates the significant quantity of mouse IgG in the complex peak frac-
tions despite the reduction of the '25I-labelled monoclonal (El versus 0)
in these fractions.
also is present in the cytoplasm of infected cells. Initial studies
on the distribution of a chlamydial genus-specific antigen were
carried out by Richmond & Stirling.') Their results, utilizing
polyclonal antibody, demonstrated membrane-bound antigen
in infected cells treated with formalin, then carefully dried. The
mosaic of membrane-bound antigen was developed by peroxi-
dase-conjugated second antibody. Our results are similar to the
immunofluorescent and membrane-bound TEM studies
reported by these authors. In another study, in which a
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Figure 7. Inhibition of polyclonal IgG binding. Binding of 1251-labelled
high titre, anti-chlamydial rabbit IgG (88MS334) to affinity-purified
GLXA ( 0 ) is inhibited by the presence of unlabelled, reactive
mouse monoclonal IgG (89MS30, IgG) causing a decrease in complex
peak c.p.m. (- --- -, 5-ml fraction pool).
demonstrated two different distributions: (i) cells whose entire
surface was stained by immunofluorescence, a pattern never
observed with anti-GLXA staining; and (ii) cells with a more
punctate staining distribution similar to that reported here. An
interesting aspect, unique to the present study, is the mosaic of
antigen distribution within the inclusion, the infected cells and
the microenvironment. The elaboration of the antigen in the
infected cell is obvious by 36 hr post-infection and detectable on
the surface of both RB and EB. In particular, significant
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Table 1. Immunoglobulin interaction with glycolipid antigen
C.p.m. shift IS. C.p.m. IgG
Sample peak change peak
Mouse monoclonal IgG
87MS4* 0 51 x 104 0-650 x 106
87MS4*+GLXA 2 40 x 104 0-950 x 106
89MS30*+control 1l60 x 104 0 352 x 106
89MS30*+GLXA 3 90x 104 0-630x 106
89MS30*+GLXA 0 23 x 104 -69 0 604 x 106
+ 89MS35
Rabbit polyclonal IgG
88MS334* +GLXA 830 x 104 1l8x 106
88MS334*+GLXA 6-3x 104 - 75 0-7x 106
+ 89MS30
88MS334*+GLXA(l) 128 5 x 104 + 54 1l4 x 106
* 1251-labelled IgG.
All control and GLXA preparations were affinity purified except (1).
This was an initial GLXA preparation eluted from Octyl-Sepharose.
ment. The enzymatic mechanism(s) involved in synthesis, the
initiation of this synthesis (whether by chlamydia or by the host
cell as directed by the organism), the mechanism of GLXA
transport through the cytoplasm to the host cell membrane and
its secretion into the microenvironment all are significant
considerations which remain to be clarified. In addition to
distribution, the present TEM observations also indicate that
the quantity of anti-GLXA mAb binding was increased when
the infection was initiated with LGV rather than serovar E. This
observation may be relevant to considerations ofLGV invasive-
ness and/or virulence. During infection by either serovar,
significant quantities ofGLXA appear and a time-course study
ofGLXA production could help determine the nature of events.
This investigation is in progress.
The data presented above also demonstrated features
regarding GLXA/antibody interaction. (i) Complexes resulted
from antigen-specific recognition by antibody and these com-
plexes could be assessed by liquid phase quantification. (ii)
Competition during liquid phase quantification provided a
means to assess an antibody for its ability to recognize the
antigen or to determine the relative abundance of anti-GLXA-
specific antibodies amongst a polyclonal population. Thus,
effective competition between different antibodies for specific
epitope binding would diminish the c.p.m. in the antigen/
antibody complexes (shift peak). However, the presence of the
unlabelled, competing antibody would be detectable by EIA
assays of complex peak fractions and these were the results
obtained during the present studies. Thus, the shift analyses, as
well as immunofluorescent staining, demonstrated that an array
of mAb have been generated which recognize GLXA and they
appear to compete for the same or an overlapping epitope.
The monoclonals tested in the present studies, with the
exception of the IgM (utilized to make the affinity column for
antigen isolation), were generated by immunization with EB-cs,
yet they recognized an antigenic determinant purified from cell
culture supernatants with an affinity chromatographic column
in which an IgM monoclonal provided the specificity. Not only
was the antigen recognized by a second monoclonal antibody,
but the specific binding between antigen and antibody was
inhibitable by yet a third IgG monoclonal also generated by
immunization with EB-cs. The specific level of inhibition
observed undoubtedly reflects differences in the concentration
and the affinity of the two monoclonals. An IgG monoclonal
antibody also was able to significantly inhibit the binding of
polyclonal rabbit antibody to tissue culture-derived GLXA.
These polyclonal antibodies are a subset of the total anti-GLXA
population, generated by EB-cs immunization, since signifi-
cantly increased binding (540/,) occurred when Ip versus Ap
GLXA was used.
Critical identification of a specific epitope, in terms of
cellular distribution or biological interaction, demands a strin-
gent analysis of the antibody utilized in defining it. That the
mAb (89MS30) has a unique specific binding site to a GLXA
epitope has been demonstrated by idiotypic analyses.'4 Anti-
idiotypic antibodies, raised in guinea-pigs, specifically inhibited
the binding of GLXA by 89MS30. Additional data (L L. An,
manuscript in preparation) have confirmed that the anti-Id is
the internal image ofGLXA. It has been shown previously2 that
human antibody generated during a natural infection with C.
trachomatis recognizes and binds GLXA purified from tissue
culture supernatants. When taken together, the present mol-
ecular shift data, along with the previous information2 4 strongly
suggests that GLXA is an immunodominant group and its
distribution among infected cells supports the suggestion that it
may be significant to infections. Additionally, a high concentra-
tion of the antibody to chlamydia is directed against this antigen
whether the host is inoculated with EB-cs (as shown here with
the rabbit antiserum) or is undergoing a natural chlamydial
infection.2 Seventy-five per cent of the rabbit anti-chlamydia
IgG antibody was inhibited by anti-GLXA monoclonal anti-
body. In the case of human anti-LGV antisera (FA titre of
> 2560) a considerable quantity of antibody was directed
toward GLXA. Thus, synthesis and release of GLXA from
LGV-infected cells (see above) coupled with high serum titres of
anti-GLXA antibodies could lead to sequelae of pathology as a
function of immune complexes.'5 At present, similar quantita-
tive data on the level of recognition for LPS or other genus-
specific antigens is not available. However, the present results
suggest that the B-cell repertoire has a number of anti-GLXA
receptor bearing cells. This probably is not due to mitogenic
expansion of the B-cell clones by GLXA since, unlike LPS, it is
not mitogenic for lymphocytes in vitro (K. Troidle, manuscript
in preparation).
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